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Abstract 
Purpose: To evaluate the cytotoxicity of pegylated nanoliposomal cisplatin on human ovarian cancer 
cell line A2780CP. 
Methods: Synthesized methoxypolyethylene glycol (mPEG) propionaldehyde was characterized by 1H-
nuclear magnetic resonance (1H-NMR) and Fourier transform infrared spectroscopy (FTIR) and used as 
coating agent for the preparation of liposomal nanodrug formulation by reverse phase evaporation 
method. The characteristics of the nanoparticles were evaluated by dynamic light scattering (DLS) and 
scanning electron microscopy (SEM). Encapsulation efficiency was determined spectrometrically at 
214.42 nm by inductively coupled plasma spectroscopy (ICP-OES). The cytotoxicity of both pegylated 
nanoliposomal and free cisplatin were evaluated by 3- [4, 5-dimethyl-2-thiazolyl] -2, 5-
diphenyltetrazolium bromide (MTT) assay and expressed as half-maximal inhibitory concentration 
(IC50). 
Results: The mean diameter and zeta potential of drug-loaded liposomal particles and empty 
nanoliposomes were 125 ± 2.9 nm and -16.6 mV, 108 ± 2.2 nm and -27.2 mV, respectively, while the 
cytotoxicity (IC50) of free cisplatin and nanodrug formulation were 93.6 ± 3.1 µg/mL and 67.8 ± 2.3 
µg/mL, respectively. In vitro toxicological results indicate that the formulation exhibited approximately 
1.4-fold cytotoxicity compared with the free drug. Drug encapsulation efficiency of the nanoliposomes 
was approximately 98 ± 1 %. 
Conclusion: The findings show that the cytotoxicity of pegylated nanoliposomal cisplatin is higher than 
that of free cisplatin in human ovarian cancer cell line A2780CP. In vivo studies are, however, required 
to ascertain its therapeutic potentials. 
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One of the most important classes of 
chemotherapeutic agents are platinum drugs 
such as cisplatin, carboplatin and oxaliplatin for 
treatment of various malignancies including 
ovarian cancer. Cisplatin is a neutral inorganic, 
square planar complex that reacts with DNA to 
induce apoptosis [1]. Along with anticancer 
activity, the drug has severe toxicity, particularly 
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nephrotoxicity [2]. It has been demonstrated that 
the high binding affinity of cisplatin to plasma 
proteins and enzymes induces this toxicity [3,16]. 
Nanoparticle-based drug delivery systems such 
as liposomes, have been widely used as 
anticancer drug carriers and simultaneously 
increase the efficacy of chemotherapeutic drugs 
[4]. Liposomes are actually vesicles consisting of 
a spherical lipid bilayer and an aqueous inner 
compartment [5,20]. 
 
However conventional liposomes have suffered 
from poor bioavailability and short blood-
circulation time, and are easily removed from the 
circulation by reticuloendothelial system (RES) 
[6,14,19]. Coating the surface of the liposomes 
with polyethylene glycol (PEG) leads to increase 
the efficacy of anticancer drugs [7-9,17]. PEG 
derivatives are synthesized polymers which have 
several advantages for pharmaceutical 
applications such as high water solubility, lack of 
toxicity and immunogenicity and rapid clearance 
from the body [10-12]. 
 
The purpose of the present study was to 
evaluate the cytotoxicity and physicochemical 





Materials and equipment 
 
Cisplatin, polyethylene glycol methylether 
(mPEG, 20KDa), 3-chloropropionaldehyde 
diethyl acetal (CPADA), sodium hydrogen 
phosphate, sodium dihydrogen phosphate, 
anhydrous sodium sulfate (Na2SO4), 
phosphatidylcoline (PC), isopropyl alcohol, 
cholesterol and tetrazolium compound (3- [ 4, 5-
dimethyl-2-thiazolyl ] -2, 5-diphenyl tetrazolium 
bromide) were purchased from Sigma-Aldrich 
Chemie (USA). Chloroform, sodium hydroxide, 
hydrochloric acid, sodium chloride and sodium 
hydrogen carbonate were obtained from Merck 
Chemical Co. (Germany). RPMI-1640 culture 
medium was purchased from Invitrogen (USA). 
All of the chemicals were of analytical grade. 
Recommended storage temperature for mPEG 
was -20 °C under inert gas stream [12]. The 
human ovarian cancer cell lines A2780CP were 
obtained from cell bank of Pasteur Institute of 
Iran. The cell lines were cultured in RPMI-1640 
medium supplemented with 10 % fetal bovine 
serum (FBS), penicillin (100 µg/mL) and 
streptomycin (100 µg/mL) at 37 °C in a 5 % CO2 
incubator. 
 
For synthesis and characterization of the 
samples, rotary evaporator (Heidolph, Germany), 
scanning electron microscope (S-4160, Hitachi, 
Japan), inductively coupled plasma spectrometer 
(ICP-OES) (Varian, Vista-MPX, Japan), dynamic 
light scattering (Malvern, Zen 3600, UK), Elisa 
microplate reader (BioTek, VT, USA), 
ultracentrifuge (Beckman Coulter, Optima L-90K, 
USA), 1H-NMR spectrometer (Bruker, 500 MHz, 
Switzerland) and FTIR spectrometer (Thermo, 




1H-NMR spectra were recorded on a Bruker 
spectrometer (500 MHZ, Switzerland) with 
deuteriated chloroform (CDCl3) as the solvent in 
sterile tubes. Tetramethylsilane was used as the 
internal reference. Chemical shifts (δ) were 
reported in ppm relative to the residual proton 




FTIR spectra were recorded on a Thermo 
spectrometer (Scientific Nicolet iS50R, Germany) 
and were scanned using potassium bromide 
pellets in the range of wavenumber 4000 -500 
cm-1. The pellets were prepared using 150 mg of 
potassium bromide and 1.5 mg of samples were 
mixed homogenously and pressed by a hydraulic 
pressure at 60 kN for 5 min. 
 
Preparation of liposome 
 
Here, 50 mg of phosphatidylcoline (PC), 10 mg 
of cholesterol and 80 mg of mPEG 
propionaldehyde (Pc/ Chol/ mPEG20000 
propionaldehyde 65: 30: 5 mole ratio) were 
dissolved in 25 mL of chloroform in a round 
bottom flask. The obtained suspension was 
stirred for 1 h at room temperature and the 
solvent was removed in a rotary evaporator 
(Heidolph, Germany) (90 rpm, 45 °C) under 
vacuum for 60 min. A thin layer of lipid was 
formed at the wall of the round bottom flask. 25 
mL of PBS (pH = 7.2 ) was added to the flask 
and was stirred for 1 h. The control solution that 
consists of empty liposomes was first prepared. 
 
Preparation of nanodrug formulation 
 
Nanoliposomal cisplatin was prepared by using a 
portion of the control solution of liposome. In this 
regard, 1 mL of cisplatin solution with 
concentration of 1000 µg/mL was added to 5 mL 
of the control solution at 25 °C and stirred 
vigorously and followed by sonicating (Elmasonic 
PH 350EL, USA) to obtain the nanodrug 
suspension with concentration of 200 µg/mL. The 
formulation was homogenized in order to reduce 
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the size of liposomes in a sonicating bath three 
times, each time for 60 s. 
 
Measurement of encapsulated cisplatin  
 
Encapsulation efficiency of the nanoliposomal 
formulation was determined by inductively 
coupled plasma spectroscopy (ICP-OES) 
(Varian, Vista-MPX, Japan). The unencapsulated 
cisplatin was separated from the suspension by 
ultracentrifugation (Beckman Coulter, Optima L-
90K, USA) (45000 rpm, 4 °C, 60 min). One 
milliliter of the supernatant was dissolved in 5 mL 
of aqua rejia (3HCl: 1HNO3) and was diluted to 
10 mL. Thereafter, the absorbance of the 
supernatant was obtained spectrometrically at 
214.42 nm. Encapsulation efficiency (EE) was 
calculated using Eq 1 [13]: 
 
EE (%) = {(Cl – Cs)/Cl}100 ………….…….. (1) 
 
where, Cl and Cs are the concentrations of 
cisplatin in the nanoliposomal formulation before 
ultracentrifugation (in µg/mL) and in the 
supernatant (in µg/mL), respectively. 
 
Characterization of nanoliposomal cisplatin 
 
Morphological studies of nanoparticles were 
studied using scanning electron microscopy 
(SEM) (S-4160, Hitachi, Japan). The nanodrug 
samples were lyophilized at -70 °C for 18 h to 
obtain dried nanodrug. The samples were 
sprinkled on a double-sided adhesive tape and 
were sputter-coated with gold. The coated 
samples were investigated using SEM at 20 kV. 
Also the mean diameter, size distribution and 
zeta potential of particles were determined by 
dynamic light scattering (DLS) (Malvern, Zen 
3600, UK). 
 
Evaluation of in vitro cytotoxicity 
 
MTT assay was used to assign cytotoxicity 
[1,18,22]. In this test, cells were cultured in 
colourless flat bottom 96-well-plate at density of 
104 cells per well in 100 µL medium and 
incubated overnight. Cells were exposed to 
different concentrations of free cisplatin and 
nanoliposomal cisplatin (6.25, 12.5, 25, 50, 100, 
200 µg/mL) for 48 h. The supernatant in each 
well was removed and 80 µL of MTT reagent (0.5 
mg/mL) was added to each well and incubated at 
37 °C for 2 h until development of formazan 
crystals. The MTT reagent was reduced by 
metabolically active cells to insoluble purple 
formazan dye crystals. The supernatant in each 
well was removed and 100 µL of isopropyl 
alcohol was added to each well to dissolve 
formazan crystals. Absorbance was measured at 
570 nm using microplate reader (BioTek, VT, 
USA). IC50 of free cisplatin and nanodrug were 
calculated by the statistical package, Pharm-PCS 
software. Then cytotoxicity of free cisplatin and 
pegylated nanoliposomal cisplatin were 
evaluated after 48 h on human ovarian cancer 
cell line A2780CP with various concentrations of 
the nanodrug formulations (6.25, 12.5, 25, 50, 
100, 200 µg/mL). Each experiment was carried 
out in triplicate on A2780CP cell line. 
 
Statistical analysis  
 
The results are presented as mean ± standard 
deviation (SD, n = 3). Statistical analysis of data 
were performed by Student’s t-test using SPSS 
software version 21.00. Differences were 




Characteristic of mPEG propionaldehyde 
 
The FTIR spectrum of synthesized mPEG 
propionaldehyde is shown in Fig. 1. The principal 
peak of the mPEG propionaldehyde was at 
2886.8 cm-1 which can be assigned to the C-H 
stretching in aldehyde group. 
 
1H-NMR (CDCl3, 500MHz, ppm): δ 9.77 (-
OCH2CH2CHO, 1H, t), δ 2.66 (-CH2CHO, 2H, q), 
δ 3.64 (PEG main chain, 1992H, m), δ 3.36 (-
OCH3, 3H, s). 
 
Characteristics of nanoliposomal cisplatin 
 
The mean diameter, size distribution and zeta 
potential of empty nanoliposomes and cisplatin-
loaded nanoliposomes are outlined in Table 1. 
Incorporation of cisplatin into nanoparticles 
increased the size, size distribution and zeta 
potential of the nanoparticles. SEM image and 
particle size distribution of nanoliposomal 
cisplatin are shown in Figs 2 and 3, respectively. 
It can be seen the most of the particles had 
spherical shape. Encapsulation efficiency was 
obtained 98 ± 1 % based on Eq. 1. 
 
Stability of nanodrug 
 
The size and zeta potential of pegylated 
nanoliposomal cisplatin were stable significantly 
at the storage time. Stability of size and zeta 
potential of nanodrug formulations were recorded 
for 4 weeks. Therefore, the pegylated 
nanoliposomal cisplatin were considered stable 
at 4 °C over the observed time. 
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Figure 2: SEM image of nanoliposomal cisplatin 
 
 
Figure 3: Particle size distribution of nanoliposomal 
cisplatin  
 
Table 1: Physicochemical properties of pegylated liposomal nanoparticles 






Empty nanoliposomes  108  2.2 -27.2 0.34 
Cisplatin-loaded 
nanoliposomes  
125  2.9 -16.6 0.55 
All data are presented as mean  SD (n=3) 
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Cytotoxicity of nanoliposomal cisplatin 
 
IC50 values obtained for free cisplatin and 
pegylated nanoliposomal cisplatin were 93.6 ± 
3.1 µg/mL and 67.8 ± 2.3 µg/mL, respectively. 
The cytotoxicity of pegylated nanoliposomal 
cisplatin is higher than that of free cisplatin on 




The chemical structure of the synthesized 
mPEG20000 propionaldehyde, as a coating 
agent in drug delivery, were confirmed by FTIR 
and 1H-NMR. In the FTIR spectrum of the 
synthesized mPEG20000 propionaldehyde there is 
a peak at 2886.8 cm-1 which can be assigned to 
the C-H stretching in an aldehyde group. In other 
words, this band confirms the presence of the 
functional aldehyde group in the samples. The 
1H-NMR spectrum of the synthesized mPEG20000 
propionaldehyde indicate the protons of the 
aldehyde group and methylene adjacent to the 
aldehyde group (CH2CHO). These proton appear 
as a triplet peak at 9.77 ppm and a quintet peak 
at 2.66 ppm. So, 1H-NMR results confirmed the 
presence of the functional aldehyde group in the 
synthesized mPEG20000 propionaldehyde. 
 
The physicochemical properties of nanoparticles 
are presented in Table 2. It can be observed that 
the size of the drug-loaded nanoparticles is 
higher than that of the empty nanoparticles. In 
addition, the zeta potential of the drug-loaded 
nanoparticles was more positive than the empty 
nanoparticles. These results are consistent with 
the results obtained by Hoseineh et al and 
Eskolaky et al [18,22]. The results of the mean 
diameter of the nanoparticles using DLS after 
their fabrication confirmed the size of 
nanoparticles in the nano scale. In the current 
study, the mean diameters of the prepared 
nanoparticles were approximately 100 nm. This 
size is less than the size of nanoparticles 
prepared by Krieger et al which is approximately 
110 nm [1]. This phenomenon can be due to the 
applied preparation method. In this study, the 
nanoliposomes were prepared using reverse 
phase evaporation (REV) method and the lipid 
composition was Pc/Chol/(mPEG20000 
propionaldehyde) in 65/30/5 mole ratio, while 
Krieger et al applied film method (FM) and the 
lipid composition was Pc/Chol/mPEG2000-PE in 
65/30/5 mole ratio [1]. The physicochemical 
properties of nanoparticles can be influenced by 
experimental conditions of manufacturing such 
as concentration, temperature and sonication 
time [15,21]. The nanoparticles prepared under 
different conditions showed smaller sizes and a 
narrower size distribution profile [8,15,22]. 
The selection of solvent was important as it 
exerts a critical influence over the reaction time 
required in the REV method. Therefore, 
chloroform and ethyl alcohol were tested as 
solvents in this study, being chloroform the most 
appropriate one, since it significantly decreased 
the reaction time. These results suggested that 
solubility in the different solvents had effect on 
nanoparticles size and the shorter solubility time, 
the lower nanoparticles size. 
 
MTT assay is a valid test to evaluate the efficacy 
of the nanodrug formulation in vitro environment, 
and hence it was used in this study to obtain the 
cytotoxicity of pegylated nanoliposomal cisplatin. 
IC50 values of pegylated nanoliposomal cisplatin 
and free drug were 67.8 µg/mL and 93.6 µg/mL, 
respectively. The results showed the IC50 of 
nanoformulation on human ovarian cancer cell 
line A2780CP were less than that of the free 
drug. The cytotoxicity of the nanoformulation was 
approximately 1.4 times that of the free drug. 
These results are consistent with the results 
obtained by Hoseineh et al and Eskolaky et al 
[18,22]. The results showed decreasing of IC50 
values of nanoformulations lead to enhance the 




Pegylated nanoliposomal cisplatin have been 
successfully synthesized by reverse phase 
evaporation method in this study. Pegylated 
nanoliposomal cisplatin shows higher cytotoxicity 
than the free drug on human ovarian cancer cell 
line A2780 CP after 48 h of incubation. These 
findings provide a new approach to the 
application of liposomal drug carriers in cancer 
chemotherapy. In vivo studies are, however, 
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